FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Described is a group of inventions involving a glucagon peptide, a pharmaceutical composition, containing said glucagon peptide in a therapeutically effective amount, and method of using said glucagon peptide for preparing a drug for treating or preventing diabetes, obesity and related diseases and conditions.
EFFECT: invention widens range of glucagon peptides.
12 cl, 1 dwg, 2 tbl, 109 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL GLUCAGON ANALOGUES | 2011 |
|
RU2559320C2 |
| STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
| DOUBLE ACYLATED GLP-1 DERIVATIVES | 2012 |
|
RU2602601C2 |
| DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
| SELECTIVE PYY COMPOUNDS AND USES THEREOF | 2014 |
|
RU2678312C1 |
| SELECTIVE COMPOUNDS OF YY PEPTIDE AND USE THEREOF | 2016 |
|
RU2726777C2 |
| ANALOGUES OF EGF(A) WITH SUBSTITUENTS-FATTY ACIDS | 2017 |
|
RU2747877C2 |
| DIPEPTIDE, CONTAINING NONPROTEINOGENIC AMINO ACID | 2012 |
|
RU2643515C2 |
| INSULIN DERIVATIVES CONTAINING ADDITIONAL DISULFIDE BONDS | 2011 |
|
RU2598273C2 |
| FGF21 DERIVATIVES AND USE THEREOF | 2015 |
|
RU2729011C2 |
